The current standard of care for the treatment of allergic airway diseasesinclude short and long acting beta-ago -nists, and inhaled or systemic corticosteroids, cromolyn and xanthines thatall have the potential of detrimental side-effects. Thepresent invention describes a new mechanistic protein-based therapeuticapproach for the treatment of allergic airway disease anddiseases associated with excessive Th2 pathology. The present inventionrelates to the surprising discovery that serum amyloid P(SAP) demonstrates a therapeutic affect in the treatment of hypersensitivedisorders.
